PVI
MRSN

Pura Vida Investments’s Mersana Therapeutics MRSN Stock Holding History

Pura Vida Investments’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,116
Closed -$2.99M – 170
2020
Q2 		$2.99M Buy
+5,116
New +$1.75M 0.29% 78
2019
Q2 		– Sell
-7,877
Closed -$1.04M – 116
2019
Q1 		$1.04M Buy
+7,877
New +$991K 0.15% 90

Other funds holding MRSN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pura Vida Investments's MRSN Position: Q3 2020 in Review

Pura Vida Investments sold out of Mersana Therapeutics (MRSN) in Q3 2020, closing a stake of 5,116 shares — an estimated $2.99M sold.

Pura Vida Investments first reported a position in MRSN in Q1 2019 and held it in 2 quarters. The position peaked at $2.99M in Q2 2020. 135 funds tracked by Wall St. Rank hold MRSN as of Q3 2020.

  • Pura Vida Investments reported no remaining Mersana Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pura Vida Investments sold 5,116 Mersana Therapeutics shares in Q3 2020, an estimated $2.99M.
  • Pura Vida Investments first reported a position in Mersana Therapeutics in Q1 2019 and held it in 2 quarters.
  • Pura Vida Investments's Mersana Therapeutics position peaked at $2.99M in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2020.

Based on Pura Vida Investments's 13F filing for Q3 2020, filed 16 Nov 2020.